Rol' i mesto tsetuksimaba v 1-y linii terapii metastaticheskogo kolorektal'nogo raka


Cite item

Full Text

Abstract

В настоящее время колоректальный рак (КРР) является одной из серьезнейших проблем здравоохранения экономически развитых стран. В мире ежегодно выявляется около 1 млн случаев заболевания, пример- но 500 тыс. больных в течение 1 года умирают. Наблюдается неуклонный рост заболеваемости как в нашей стране, так и во всем мире. В Российской Федерации исторически статистические показатели рассчитываются раздельно для злокачественных опухолей ободочной и прямой кишки. В России в 2007 г. стандартизованный показатель заболеваемости раком ободочной кишки составил 13,05 и раком прямой кишки – 10,43 на 100 тыс. населения. Это разделение несколько «маскирует» истинную картину заболеваемости КРР. За последние 5 лет заболеваемость КРР повысилась на 12%. В Российской Федерации доля КРР среди злокачественных заболеваний органов пищеварения достигла 42%. Динамика смертности от КРР относительно стабильна. В России в 2007 г. стандартизованный показатель смертности от рака толстой кишки составил 8,18 и рака прямой кишки – 6,66 на 100 тыс. населения. Заболеваемость КРР выше в экономически развитых странах, чем в развивающихся. В Европе КРР ежегодно диагностируется более чем у 370 тыс. пациентов, что составляет 13% от всей онкологической заболеваемости и вызывает около 200 тыс. смертельных исходов. Серьезная проблема заключается и в том, что до 70% пациентов обращаются к онкологам с IIB–IV (DUKES B2 – D) стадией заболевания, т.е. тогда, когда только оперативное лечение не может обеспечить гарантированное стойкое излечение.

About the authors

M V Kopp

Самарский областной клинический онкологический диспансер

I A Koroleva

Самарский областной клинический онкологический диспансер

References

  1. Злокачественные новообразования в России в 2007 г. (заболеваемость и смертность). Под ред. В.И.Чиссова, В.В.Старинского, Г.В.Петровой. М.: ФГУ МНИОИ им. П. А. Герцена Росмедтехнологий, 2008.
  2. Состояние онкологической помощи населению в России в 2007 г. Под ред. В.И.Чиссова, В.В.Старинского, Г.В.Петровой. М.: ФГУ МНИОИ им. П. А. Герцена Росмедтехнологий, 2008.
  3. Статистика злокачественных новообразований в России и странах СНГ в 2006 г. Под ред. М.И. Давыдова, Е.М. Аксель. Вестн. РОНЦ им. Н.Н.Блохина РАМН. 2008; 19 (2, прил. 1): 3–154.
  4. Parkin D.M., Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 72–108.
  5. Cunningham D, Findley M. The Chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993; 29A (15): 2077–9.
  6. Macdonald J.S. Adjuvant therapy of colon cancer. CA Cancer J Clin 1999; 49 (4): 202–19.
  7. de Gramont A, Bosset J.F., Milan C et al. Randomized trial comparing monthly low - dose leucovorin and fluorouracil bolus with bimonthly high - dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a Freanch Intergroup study. J Clin Oncol 1997; 15: 803–15.
  8. Douillard J.Y., Cunningham D, Roth A et al. Irinotecan combined will fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: A multicenter randomised trial. Lancet 2000; 355 (9209): 1041–7.
  9. Saltz L, Cox J, Blanke Ch et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New Engl J Med 2000; 343 (13): 905–14.
  10. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first - line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18 (16): 2938–47.
  11. Giacchetti S, Perpoint B, Zidani R et al. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil - Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer. J Clin Oncol 2000; 18 (1): 136–6.
  12. Grothey A et al. Bolus 5-fluoroureacil/folonoc acid vs. Weekly high - dose 24H 5-Fu Infusion/FA + Oxaliplatin in advanced colorectal cancer. Results of a phase III study Proc Am Soc Clin Oncol 2001, abstr. 496.
  13. Goldberg R.M., Sargent D.J., Morton R.F. et al. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. J Clin Oncol 2004; 1: 23–30.
  14. Grothey A, Sargent D, Goldberg R.M. et al. Survival of patients with advanced colorectal cancer improves with availability of fluorouracil - leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209–14.
  15. de Gramont A, Cervantes A, Andre T et al. OPTIMOX study: FOL- FOX7/LV5FU compared to FOLFOX4 in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2004; 23 (251): abstr 3525.
  16. Kabbinavar F, Hurwitz H, Fehrenbacher L et al. Phase II trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60–5.
  17. Kabbinavar F et al. Addition of Bevacizumab to bolus fluorouracil and leucovorin in first - line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697–705.
  18. Hurwitz H et al. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer: results of a randomized phase III trial. N Engl J Med 2004; 350 (23): 2335–42.
  19. Cassidy J, Clarke S, Diaz-Rubio E et al. XELOX compared to FOL- FOX4: Survival and response results from XELOX-1/NO16966, a randomized phase III trial of first - line treatment for patients with metastatic colorectal cancer (MCRC) (abstract 4030). J Clin Oncol 2007; 25 (18S): 171.
  20. Saltz L, Clarke S, Diaz-Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX- 1/NO16966, a randomized phase III trial in first - line metastatic colorectal cancer (abstract 4028). J Clin Oncol 2007; 25 (18S): 170.
  21. Saltz L, Clarke S, Diaz-Rubio E et al. Bevacizumab in Combination With Oxaliplatin - Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. J Clin Oncol 2008; 26 (12): 2013–9.
  22. Larsson O et al. Role of insulin - like growth factor receptor signaling in cancer. Br J Cancer 2005; 92: 2097–101.
  23. Samani A et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28 (1): 20–47.
  24. Orton R.J., Sturm O.E., Vyshemirsky V et al. Computational modelling of the receptor - tyrosine - kinase - activated MAPK pathway. Biochem J 2005; 392: 249–61.
  25. Avruch J, Khokhlatchev A, Kyriakis J et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Rec Prog Hormone Res 2001; 56: 127–55.
  26. Moosmann N, Heinemann V. Cetuximab in the treatment of metastatic colorectal cancer. Expert Opin Biolog Ther 2007; 7 (2): 243–56.
  27. Adenis A, Aranda Aguilar E, Robin Y.M. et al. Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a lage scale metastatic colorectal cancer (mCRC) trial. J Clin Oncol 2005; 23: 278 (abstr. 3630).
  28. Cuningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan - refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45.
  29. Folprecht G, Lutz M.P., Schoffski P et al. Cetuximab and irinotecan/5- fluorouracil/folinic acid is a save combination for the first - line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450–6.
  30. Goldstein N.S., Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implcations for a standardized scoring system. Cancer 2001; 92: 1331–46.
  31. Saltz L.B., Meropol N.J., Loehrer P.J.S.r et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–8.
  32. Goldstein N.I., Prewett M, Zuklys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311–8.
  33. Li S, Schmitz K.R., Jeffrey P.D. et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301–11.
  34. Lenz H.-J. Cetuximab in the management of colorectal cancer. Biologics: Targets Therapy 2007; 1 (2): 77–91.
  35. Saltz L.B., Meropol N.J. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer thet expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–8.
  36. Lentz H-J, Mayer R.J. et al. Consistent response to treatment with cetuximab monoterapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23 (16s): Abstr. 3536.
  37. Jonker D, Karapetis C.S., Moore M et al. Randomized phase III trial of cetuximab montherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal cancer: A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIG CTG) and The Australasian Gastrointestinal Trials Group (AGITG) Proc of ASCO 2007; Abstr. ALB-1.
  38. Cunningham D, Humblet Y et al. Cetuximab monothrerapy and cetuximab plus irinotecan in irinotecan - refractory colorectal cancer. N Engl J Med 2004; 351: 337–45.
  39. Salyz L, Rubin et al. Cetuximab (IMC-C225) plus irinotecan (CPT-is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc AMSoc Clin Oncol 2001; 20: 3a (abstr 7).
  40. Siena S, Glynne-Jones R et al. MABEL: A large multinational study of cetuximab plus irinotecan in mCRC after irinotecan failure update on infusion - related reactions. ASCO 2007; abstr. 353.
  41. Souglakos J, Kalykaki A et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin - based chemotherapy. Ann Oncol 2006; 1: 1–6.
  42. Sobrero A.F., Fehrenbacher L, Rivera F et al. Randomized phase III trial of cetuximab plus irinotecan vs. irinotecan alone for metastatic colorectal cancer (mCRC) in 1298 patients (pts) who have failed prior oxaliplatin - based therapy: the EPIC trial. Proc of ASCO 2007; Abstr LB-2.
  43. Van Cutsem E, Land I, Haens G et al. KRAS status and efficacy in the CRISTAL study: 1st - line treatment of patients with metastatic colorectal cancer (mCRC) receiving FOLFIRI with or without Cetuximab. ESMO 2008; Abstr. 710.
  44. Van Cutsem E, Lang I, D'haens G. KRAS status and efficacy in the first - line treatment of patents with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience J Clin Onc 2008; 26 15S (20 Suppl.): Abstr. 2.
  45. Van Cutsem E, Lang I, D'Haens G et al. The CRYSTAL study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mCRC receiving first - line treatment with cetuximab or cetuximab plus FOLFIRI. WCGIC 2008, Abstr. 471.
  46. Van Cutsem E et al. CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in rst - line metastatic colorectal cancer (mCRC). Eur J Cancer 2007; 5: 235, abstr. 3001.
  47. Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5- FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first - line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. ASCO 2007; Abstr. 4000.
  48. Schuch G, Staroslawska E, Nowacki M et al. Cetuximab plus 5- Fu/FA/Oxaliplatin (FOLFOX-4) In the first - line treatment of MCRC: Opus, a Phase II study. Proceedings from the Ninth World Congress on Gastrointestinal Cancer. Barcelona, Spain. 2007; Abstr. 022.
  49. Brodowicz T, Wrba F, Koza I. KRAS status and efficacy of first - line treatment of metastatic colorectal cancer patients with FOLFOX 6 + cetuximab or FOLFIRI + cetuximab: The CECOG/CORE1.2.001 experience. ASCO GI 2009; Abstr. 381.
  50. Saltz L.B., Lenz H, Hochster H et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan - refractory colorectal cancer. ASCO 2005; Abstr. 3508.
  51. Punt C.J. et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). ASCO 2008; Abstr. LBA-4011.
  52. Punt J, Pander J, Tol J. Pharmacogenetic (PGx) analysis of toxicity after oxaliplatin (Ox), capecitabine (Cap), bevacizumab (Bev) and cetuximab (Cet) therapy for advanced colorectal cancer (ACC): First results from the Dutch Colorectal Cancer Group (DCCG)-CAIRO2 trial. J Clin Oncol 2008; 26 (suppl.): abstr. 2574.
  53. Nordinger B, Van Custem E, Rougier P et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment group. Eur J Cancer 2007; 43: 2037–45.
  54. Van Custem E, Nordinger B, Adam R et al. Towards a pan - Europen concensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212–21.
  55. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long - term survival. Ann Surg 2004; 240: 644–58.
  56. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311–9.
  57. www.livermetsurvey.org
  58. Tanaka K, Adam R, Shimada H et al. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90: 963–9.
  59. Allen P.J., Kemeney N, Jarnagin W et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003; 7: 109–15.
  60. Adam R, Pascal G, Castaing D et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052–61.
  61. Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006; 243: 1–7.
  62. Folprecht G, Gruenberger T, Hartmann J.T. et al. Randomized multicenter study of Cetuximab plus FOLFOX or plus FOLFIRI in neoadjuvant treatment of non - resectable colorectal liver metastases (CELIM-study). ESMO 2008; Abstr No: 510.

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies